Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma

1 May 2005

Abstract excerpt

The presence of t(4;14)(p16.3;q32.3) in multiple myeloma cells results in dysregulated expression of the fibroblast growth factor receptor 3 (FGFR3). FGFR3 acts as an oncogene to promote multiple myeloma cell proliferation and antiapoptosis. These encourage the clinical development of FGFR3-specific inhibitors. Three short hairpin RNAs (shRNA) targeting different sites of FGFR3 were selected and subsequently...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Eosinophilic Disorders and Syndromes
Share to Fibroblast Growth Factor Research
Share to Kruppel-like factors research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15897243
DOI: 10.1158/1535-7163.mct-04-0330

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myelomaPMID 15897243Read ↗

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myelomaSemantic proximity Read ↗

The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategiesSemantic proximity Read ↗

Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.Semantic proximity Read ↗

MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cellsSemantic proximity Read ↗

MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma.Semantic proximity Read ↗

Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patientsSemantic proximity Read ↗

Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruptionSemantic proximity Read ↗

Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discovery.Semantic proximity Read ↗

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignanciesSemantic proximity Read ↗

Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.Semantic proximity Read ↗

The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression.Semantic proximity Read ↗

Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.